Day One – Talk Bio

Actionable Insights Powered by AI

Ipsen Secures Ex-US Rights to Day One’s Pediatric Cancer Medication with $111M Upfront Investment

9 months ago talkbio0Tagged Day One, ex-US, Ipsen, Malignant Childhood Neoplasm, rights, tovorafenib, upfront

Ipsen, Day One, Pediatric Cancer, Tovorafenib, Ex-US Rights, $111M Upfront Investment

FDA Fast-Tracks Day One’s Innovative Therapy for Pediatric Brain Tumors

1 year ago talkbio0Tagged Accelerated, Approved, Brain Neoplasms, Cancer Therapeutic Procedure, cellular targeting, Child, Day One, Glioma, Pediatric brand name, United States Food and Drug Administration

FDA, accelerated approval, Day One, targeted treatment, pediatric brain tumors, glioma, children, cancer treatment, innovative therapy.